Haddad Chantal is a seasoned Clinical Site and Start-Up Associate at Novo Nordisk, bringing over 14 years of specialized experience in Trial Master File (TMF) management and regulatory document collection. Her extensive background encompasses a deep understanding of the site start-up process, essential document requirements,...
Haddad Chantal is a seasoned Clinical Site and Start-Up Associate at Novo Nordisk, bringing over 14 years of specialized experience in Trial Master File (TMF) management and regulatory document collection. Her extensive background encompasses a deep understanding of the site start-up process, essential document requirements, and adherence to ICH-GCP regulations, making her a pivotal asset in the execution of high-quality clinical trials.
In her current role, Haddad is instrumental in delivering comprehensive services that support the meticulous planning and execution of clinical trials. She is adept at ensuring that all activities align with established targets, while also maintaining open lines of communication to provide timely updates to stakeholders. Her proactive approach to risk identification and mitigation planning for assigned clinical trial sites has proven invaluable in navigating the complexities of clinical research.
Haddad's expertise extends to her decade-long experience as a Reconciliation Clinical Trial Associate (CTA), where she performed quality and pre-audit reviews of investigator files across various late-stage therapeutic areas. This role honed her skills in quality reviews and reinforced her commitment to maintaining the highest standards of compliance and data integrity. Proficient in utilizing tools such as Electronic Trial Master File (eTMF) and Clinical Trial Management Systems (CTMS), along with advanced capabilities in Microsoft Excel, she effectively drives and tracks site activation and start-up activities.
Through her dedication and expertise, Haddad Chantal continues to contribute significantly to the advancement of clinical research at Novo Nordisk, ensuring that trials are not only compliant but also positioned for success.
